>> Go to all press releases

Lucerne, November 7, 2022 – November is Lung Cancer Awareness Month. A month dedicated to those affected by lung cancer and to raise public awareness of the causes, early detection and prevention of the disease. MSD is participating in the worldwide awareness campaign – in Switzerland among other things by supporting activities of the newly founded patient organization “Leben mit Lungenkrebs” (“Living with Lung Cancer”) and launching a new website for lung cancer patients and their relatives.

Lung cancer is the second most common type of cancer and the leading cause of cancer death worldwide.1 As one of the leading companies in oncology, MSD is committed to cancer research and improving cancer care. “Particularly in November, we support initiatives and projects that connect lung cancer patients and offer advice and support to help them living with their disease. We are also committed to raising awareness of the disease among the general public. We want to encourage everyone to prioritize their health, to be aware of the risks for lung cancer and to get checked by a doctor if they have symptoms,” says Will Wooding, Business Unit Director Oncology at MSD Switzerland.

MSD supports new patient organization for lung cancer patients

The newly founded patient organization “Leben mit Lungenkrebs” (“Living with Lung Cancer”) is the first platform exclusively for lung cancer patients and their relatives. In addition to providing opportunities to connect and exchange, the organization offers events for those affected, provides valuable information materials and raises awareness of the disease through educational work. MSD is proud to support the organization. The first event for those affected will be held in Zurich on November 26, 2022.

More information

MSD launches website for lung cancer patients and their relatives

Just in time for Lung Cancer Awareness Month, MSD has expanded its patient portal MSD Gesundheit with information about lung cancer. The new website provides detailed information on the main types of lung cancer, diagnosis and treatment options, answers to the most frequent questions and information on where patients can get advice and support. In addition, lung cancer patients can download various checklists with questions to help them prepare for their next doctor’s appointment.

Visit the website

Facts about lung cancer

Lung cancer is the second most common type of cancer and the leading cause of cancer death worldwide.1 In Switzerland around 4,700 people are diagnosed with it every year and about 3,300 die from it.2 Almost all newly diagnosed patients are over 50 years of age at the time of diagnosis.3 The main types of lung cancer are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), which grow differently and are treated differently.4 The most common symptoms include among others ongoing or worsening cough, coughing up blood, chest pain and hoarseness.5 People with these symptoms should visit their doctor, because the earlier lung cancer is detected, the bigger the chances of a cure. The most important way to prevent lung cancer is to avoid tobacco smoke.6

Lung cancer is not a death sentence

Most lung cancers do not cause any symptoms until they have spread.5 Therefore, they are often diagnosed at a late stage.5 If the cancer has already spread outside the lungs, the prognosis for patients is very poor.7 But because of new effective treatments, this is changing. Over the past decades, significant advancements have been made in the treatment of lung cancer. Research has led to more survivors and more hope to those still facing the disease.7

More information

References

  1. https://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf, last access 24.10.2022
  2. https://www.krebsliga.ch/ueber-krebs/zahlen-fakten/-dl-/fileadmin/downloads/sheets/zahlen-krebs-in-der-schweiz.pdf, last access 24.10.2022
  3. https://www.krebsliga.ch/ueber-krebs/krebsarten/lungenkrebs-bronchialkarzinom/, last access 24.10.2022
  4. https://www.cdc.gov/cancer/lung/basic_info/what-is-lung-cancer.htm, last access 24.10.2022
  5. https://www.cancer.org/cancer/lung-cancer/detection-diagnosis-staging/signs-symptoms.html last access 24.10.2022
  6. https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/risk-factors-and-prevention, last access 24.10.2022
  7. https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics, last access 24.10.2022

About MSD Merck, Sharp & Dohme

At MSD Merck, Sharp & Dohme, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on TwitterLinkedIn and YouTube.

MSD Merck, Sharp & Dohme in Switzerland

In Switzerland, MSD Merck, Sharp & Dohme employs around 1,000 people at five sites in the cantons of Lucerne and Zurich. At our site in Zurich, in “The Circle”, we operate the newly opened global innovation and development hub. Our main therapeutic areas are oncology, infectious diseases, immunology, and diabetes. We also operate a broad portfolio of vaccines for the prevention of diseases in children, adolescents, and adults. Switzerland is part of MSD’s global clinical research program with more than 30 clinical trials annually. At our site in Schachen, we manufacture drugs for global clinical trials and operate a forensic laboratory. MSD also takes local responsibility for the community and has been involved in the “Trendtage Gesundheit Luzern” and the Alliance Health competence. In 2022, MSD received the “Top Employer Switzerland” award for the tenth time in a row.

For more information, please visit msd.chde.msd-animal-health.ch and follow us on TwitterLinkedInFacebook and YouTube.

Media contact

Dr. phil. Caroline Hobi

Associate Director Policy & Communications

media.switzerland@msd.com | Tel. 058 618 30 30

Copyright © 2022 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

CH-NON-01948

>> Go to all press releases

>> Go to all press releases

Lucerne, October 3, 2022 – October is Breast Cancer Awareness Month, a global initiative to raise awareness on the prevention and early detection of breast cancer, the most common cancer in women. MSD supports these efforts with various initiatives, including the awareness campaign «Sag Nein zu Brustkrebs, sag Ja zur Früherkennung!» and the launch of a website for breast cancer patients and their relatives.

As one of the world’s leading companies in oncology, MSD supports the Breast Cancer Awareness Month October. “Breast cancer is the most common cancer in women in Switzerland and worldwide. At MSD, we show solidarity with those facing breast cancer. We do everything we can to drive further innovation that will help to save and improve lives. Especially in October we support various activities to educate about the importance of prevention and early detection – because the earlier breast cancer is detected and treated, the better the chances of a cure.”, says Dr. Ans Heirman, Managing Director MSD Switzerland.

Awareness Campaign «Sag Nein zu Brustkrebs, sag Ja zur Früherkennung!»

To mark Breast Cancer Awareness Month October, MSD supports the awareness campaign “Sag Nein zu Brustkrebs, sag Ja zur Früherkennung!” (Say no to breast cancer, say yes to early detection) in partnership with EUROPA DONNA Switzerland. On 4 days in October, events will be held in the pink container ”Pink Cube” in Baden and Zurich, where gynecologists will offer free consultations and breast examinations to interested visitors. Everyone is invited to visit the Pink Cube and take advantage of the free consultation and breast examination.

For more information please visit the Website

MSD launches website for breast cancer patients and their relatives

Just in time for Breast Cancer Awareness Month October, MSD is expanding its patient portal MSD Gesundheit with information about breast cancer. The new website provides detailed information about the disease including risks and options for prevention, early detection and treatment of breast cancer. In addition, the website offers answers to the most frequently asked questions about breast cancer and information on where affected people can get advice and support.

“The diagnosis of breast cancer is the first step on a path that raises many questions, causes uncertainties and fears. With the information on the patient portal MSD Gesundheit, we want to offer an information platform that helps patients and their relatives to better understand their disease and offers them guidance on their journey,” says Will Wooding, Director Business Unit Oncology, MSD Switzerland.

About breast cancer

Breast cancer is the most common type of cancer in women and accounts for almost one third of all cancer diagnoses.1 In Switzerland, around 6,300 women and 50 men are diagnosed with breast cancer, around 1,410 people die of it every year.1 The rate of disease increases with age.2 Nevertheless, a quarter of all patients are younger than 50 at the time of diagnosis.2 Worldwide, breast cancer is the most common cancer diagnosed, affecting more than 2.3 million people.3

The earlier breast cancer is detected and treated, the better the chances of cure.2 In addition to the preventive checkup at the gynecologist, every woman should palpate her breast regularly to notice changes. For women over 50, mammography is recommended to detect breast cancer at an early stage.2

Today, significantly fewer women die from breast cancer than twenty years ago.4 This is due to improved early detection and new and more advanced therapies.4 Treatment options include surgery, chemotherapies, radiotherapies, anti-hormone therapies, immunotherapies and targeted therapies. Often, different types of therapy are combined.

More information

References

  1. https://www.krebsliga.ch/ueber-krebs/zahlen-fakten/, last access 26.9.2022
  2. https://www.krebsliga.ch/ux/brustkrebs-ux20, last access 26.09.2022
  3. https://www.who.int/news-room/fact-sheets/detail/breast-cancer, last access 26.09.2022
  4. https://www.nkrs.ch/assets/files/publications/Krebsbericht2021/1177-2100-de.pdf, last access 26.09.2022

About MSD Merck, Sharp & Dohme

At MSD Merck, Sharp & Dohme, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on TwitterLinkedIn and YouTube.

MSD Merck, Sharp & Dohme in Switzerland

In Switzerland, MSD Merck, Sharp & Dohme employs around 1,000 people at five sites in the cantons of Lucerne and Zurich. At our site in Zurich, in “The Circle”, we operate the newly opened global innovation and development hub. Our main therapeutic areas are oncology, infectious diseases, immunology, and diabetes. We also operate a broad portfolio of vaccines for the prevention of diseases in children, adolescents, and adults. Switzerland is part of MSD’s global clinical research program with more than 30 clinical trials annually. At our site in Schachen, we manufacture drugs for global clinical trials and operate a forensic laboratory. MSD also takes local responsibility for the community and has been involved in the “Trendtage Gesundheit Luzern” and the Alliance Health competence. In 2022, MSD received the “Top Employer Switzerland” award for the tenth time in a row.

For more information, please visit msd.chde.msd-animal-health.ch and follow us on TwitterLinkedInFacebook and YouTube.

Media contact

Dr. phil. Caroline Hobi

Associate Director Policy & Communications

media.switzerland@msd.com | Tel. 058 618 30 30

Copyright © 2022 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

CH-NON-01894

>> Go to all press releases

Go to all press releases

Lucerne, 7 September 2022 – MSD (Merck Sharp & Dohme) group Switzerland celebrated the groundbreaking ceremony for the new quarter on the Rösslimatt site in Lucerne today with SBB and partners. After completion, 650 employees from three of the five MSD Switzerland branches will be working there. The modern premises are designed to promote integrated, sustainable working practices and synergies.

MSD is pleased to participate in today’s kick-off for the construction of the centrally located Rösslimatt Quarter, which is being built near the railway station, next to the new location of the Lucerne University. On 15,000 m2 of rented space, MSD will in future unite three of the five locations and thus 650 workstations, with an expansion option of up to 850 workstations, at a common address. With the move to the planned completion in 2025, MSD is consciously remaining loyal to Lucerne. The city and canton have supported MSD for around 60 years with a stable and reliable environment. This is a valuable prerequisite for achieving the company’s goal of using leading-edge science to save and improve lives around the globe.

Thus, with the move, MSD is not only relying on new impulses for even more intensive cross-team collaboration, but also on the expansion of existing synergies. “At MSD, the ways of working are anchored in the corporate strategy,” explains Dr. Ans Heirman, Managing Director of MSD Switzerland, “Rösslimatt, with its modern space concept, will enable us to really live these in our everyday work life – for example, agile, hybrid, team-based working. The new headquarters for the Swiss and regional business also strengthens our image as a top employer in Lucerne and far beyond the region and is expected to attract more curious, innovative minds”, continues Heirman.

An important aspect in the decision to move into the new location is also the aspect of sustainability. MSD wants to create a safe, sustainable and healthy future for people and the community through a sense of responsibility. It is therefore significant that “Rösslimatt” is certified, among other things, as a “2000-watt site under development” and is thus committed to an enormously high sustainability standard that extends over the entire life cycle of the project from planning, through construction, to operation. For MSD, in addition to sustainable real estate management during construction, the optimization of resource use at the workplace and energy-saving and environmentally friendly mobility after occupation of the future site also play a key role. Thanks to the optimal connection to the train station and the city center, the best conditions are given here.

The Rösslimatt site is intended to function as a hub of science, research and creativity. “We are convinced that in the future there will be a variety of synergies beyond the boundaries of the company. We are delighted that MSD will be moving into the heart of the Rösslimatt quarter and thus becoming part of this innovative and vibrant area,” said Fabian Peter, Head of the Department of Construction, Environment and Economic Affairs.

About MSD Merck, Sharp & Dohme

At MSD Merck, Sharp & Dohme, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on TwitterLinkedIn and YouTube.

MSD Merck, Sharp & Dohme in Switzerland

In Switzerland, MSD Merck, Sharp & Dohme employs around 1,000 people at five sites in the cantons of Lucerne and Zurich. At our site in Zurich, in “The Circle”, we operate the newly opened global innovation and development hub. Our main therapeutic areas are oncology, infectious diseases, immunology, and diabetes. We also operate a broad portfolio of vaccines for the prevention of diseases in children, adolescents, and adults. Switzerland is part of MSD’s global clinical research program with more than 30 clinical trials annually. At our site in Schachen, we manufacture drugs for global clinical trials and operate a forensic laboratory. MSD also takes local responsibility for the community and has been involved in the “Trendtage Gesundheit Luzern” and the Alliance Health competence. In 2022, MSD received the “Top Employer Switzerland” award for the tenth time in a row.

For more information, please visit msd.chde.msd-animal-health.ch and follow us on TwitterLinkedInFacebook and YouTube.

Media department MSD Switzerland

Jean-Blaise Defago (Policy & Communications Director)

media.switzerland@msd.com | Tel. 058 618 30 30

Copyright © 2022 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

CH-NON-01788

>> Go to all press releases

Go to all press releases

Lucerne, 5th September 2022 – This year, for the first time, MSD (Merck Sharp & Dohme AG) Switzerland is event partner of the Race for Life bicycle marathon in support of cancer patients and cancer research in Switzerland. In addition to financial support, the event on September 11 in Bern offers an important opportunity for a much-needed collaboration in cancer care.

On September 11, for the 12th consecutive year, Swiss cyclists will embark on a tour for even better cancer care in the future – the Race for Life. The individual cyclists and teams will complete the circuits over Bern, the old town, Wabern, Gurten and Längenberg, over eight hours as often as possible or as they please. The event focuses on supporting three institutions: The Bern Cancer League, the Swiss Association for Clinical Cancer Research (SAKK) and the Swiss Cancer Foundation. “MSD Switzerland is honored to be a partner for the first time this year” emphasizes Dr. Ans Heirman, Managing Director MSD Switzerland, “and not only as a sponsor, but also with numerous personal commitments! More than 70 colleagues are participating as cyclists and over 10 MSD employees are supporting on site as volunteers.” 

Together for an optimized supply landscape

Cancer remains one of the greatest challenges for the Swiss healthcare system. One in three people will develop cancer in the course of their lives. This means that around 40,000 people in Switzerland are confronted with this diagnosis every year.1 Each of these patients has a long, usually complex journey ahead of them, which requires coordinated treatment management.2 Unfortunately, this is still contrasted by a highly fragmented cancer care landscape without a structured national plan for cancer control. In addition, the COVID-19 pandemic has resulted in delays in the screening, diagnosis and treatment of cancer patients.

MSD has a long history of bringing forward innovative medicines. In the field of oncology, we focus on immunotherapy, which aims to activate the body’s own immune system to fight tumors. Our relentless commitment to research and development has enabled us to establish an exceptionally broad research program worldwide.

Beyond the charitable purpose, the Race for Life offers an important opportunity to draw attention to these existing challenges, to inform people about the topic of cancer care, to motivate the early detection of symptoms, and to make a real difference. “Only by joining forces we can create structure at regional and national level that make the best possible treatment available to Swiss cancer patients in a timely manner,” says Will Wooding, Director Business Unit Oncology, MSD Switzerland, “It’s time to build a coalition of all interested stakeholders and pedal together in solidarity. Together we can build an optimized cancer care landscape for those suffering with cancer in Switzerland!”

Survey on Cancer Care in Switzerland

In a representative survey of the population conducted by MSD in cooperation with the gfs.bern research institute, the quality of care for cancer patients was examined. This is considered good or very good by almost 90 percent of the population. However, the results of the study also clearly show that, on closer examination, there is still a clear need for action. Among all respondents, about 15 percent were dissatisfied with early cancer detection and cancer prevention. Almost a quarter could also imagine better psychological care. Download Report

À propos cancer…Human papillomavirus (HPV) infection and associated cancers are still a neglected disease

HPV is widespread and the diseases associated with it are often underestimated. Every day in Switzerland, more than 1 person develops HPV-related cancer. MSD is committed globally to advance the elimination of HPV-related cancers. In Switzerland, the HPV Alliance was launched in June to work together to raise awareness of HPV among the Swiss population, strengthen prevention measures and create further data foundations.

About Race for Life

The Race for Life will start on Sunday, 11 September 2022 at 10:00 am, on the Bundesplatz in Bern. You can also support the event as a private person: as a cyclist individually or in a team, as a volunteer or as a sponsor. Registration is possible at raceforlife.ch.

References

  1. Swiss Cancer Report 2021 https://dam-api.bfs.admin.ch/hub/api/dam/assets/19305696/master
  2. B. Lomazzi, B. Borisch. Game changer in cancer treatment in Switzerland. Journal of Cancer Policy 33 (2022).

About MSD Merck, Sharp & Dohme

At MSD Merck, Sharp & Dohme, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on TwitterLinkedIn and YouTube.

MSD Merck, Sharp & Dohme in Switzerland

In Switzerland, MSD Merck, Sharp & Dohme employs around 1,000 people at five sites in the cantons of Lucerne and Zurich. At our site in Zurich, in “The Circle”, we operate the newly opened global innovation and development hub. Our main therapeutic areas are oncology, infectious diseases, immunology, and diabetes. We also operate a broad portfolio of vaccines for the prevention of diseases in children, adolescents, and adults. Switzerland is part of MSD’s global clinical research program with more than 30 clinical trials annually. At our site in Schachen, we manufacture drugs for global clinical trials and operate a forensic laboratory. MSD also takes local responsibility for the community and has been involved in the “Trendtage Gesundheit Luzern” and the Alliance Health competence. In 2022, MSD received the “Top Employer Switzerland” award for the tenth time in a row.

For more information, please visit msd.chde.msd-animal-health.ch and follow us on TwitterLinkedInFacebook and YouTube.

Media department MSD Switzerland

Jean-Blaise Defago (Policy & Communications Director)

media.switzerland@msd.com | Tel. 058 618 30 30

Copyright © 2022 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

CH-NON-01799

>> Go to all press releases

Zurich Pride will take place on 17.6 and 18.6.  The LGBTIQ* festival attracts thousands of supporters and friends of the LGBTIQ* community to Zurich every year. MSD Merck Sharp & Dohme is involved as a Cooperation Partner.

The slogan for this year’s Zurich Pride, the largest event of the Swiss LGBTIQ* community, is “trans – living diversity”. For the first time in the history of Zurich Pride, the focus will be on the legal situation and challenges of trans people.

The association “Zurich Pride Festival” promotes and demands acceptance as well as equality of the LGBTIQ* way of life in public and in everyday life. The highlight of the Zurich Pride Festival is the traditional demonstration parade through downtown Zurich. This is intended to draw the attention of the population to the political and social concerns of LGBTIQ*.

“Diversity and inclusion are essential and daily lived values for MSD, therefore we are especially happy to support Zurich Pride as a cooperation partner” Phillipe Zaoui, Brand & Customer Manager Hospital Acute Care and Rainbow Alliance Lead, MSD Switzerland.

Diversity & Inclusion

Over the past five years, we have strengthened our commitment to making diversity and inclusion (D&I) a central strategy for business growth. At MSD Switzerland we believe that a diverse and inclusive workforce inspires innovation and is fundamental to our company’s success. While there has been great progress when it comes to LGBTIQ* rights, more work needs to be done — and we’re proud to play an important role in promoting diversity and inclusion. MSD has a longstanding tradition of supporting the LGBTIQ* community, in our company and beyond. Having an environment comprised of people from different dimensions of diversity also helps us better understand the unique needs of the patients, customers, and health care providers we serve.

About MSD Merck, Sharp & Dohme

At MSD Merck, Sharp & Dohme, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on TwitterLinkedIn and YouTube.

MSD Merck, Sharp & Dohme in Switzerland

In Switzerland, MSD Merck, Sharp & Dohme employs around 1,000 people at five sites in the cantons of Lucerne and Zurich. At our site in Zurich, in “The Circle”, we operate the newly opened global innovation and development hub. Our main therapeutic areas are oncology, infectious diseases, immunology, and diabetes. We also operate a broad portfolio of vaccines for the prevention of diseases in children, adolescents, and adults. Switzerland is part of MSD’s global clinical research program with more than 30 clinical trials annually. At our site in Schachen, we manufacture drugs for global clinical trials and operate a forensic laboratory. MSD also takes local responsibility for the community and has been involved in the “Trendtage Gesundheit Luzern” and the Alliance Health competence. In 2022, MSD received the “Top Employer Switzerland” award for the tenth time in a row.

For more information, please visit msd.ch, de.msd-animal-health.ch and follow us on Twitter, LinkedIn, Facebook and YouTube.

CH-NON-01711 / 06_2022


Go to all press releases

In collaboration with the research institute gfs.bern, MSD Switzerland has conducted the first ever representative survey of the population on the quality of cancer care in Switzerland. On the one hand, the survey found that the care situation is assessed as being good to very good – especially by cancer sufferers themselves. On the other hand, there is a definite need for action in the areas of prevention, early detection as well as psychological care during and after the disease.   

Swiss citizens take a keen interest in the nation’s health policy. According to the new survey, 80 percent of the population are interested in health issues. Some 1,500 people from all over Switzerland participated in the representative survey commissioned by MSD and conducted for the first time by gfs.bern. Its key finding was that the quality of care for cancer patients is considered good or very good by almost 90 percent of the population.

Good to very good ratings for cancer care


Over 40,000 new cases of cancer are diagnosed in Switzerland every year. At the same time, fewer people are dying from malignant tumours than in the past1. In other words, there are more and more people in Switzerland who are living with cancer or have overcome the disease. In the present survey, 95 percent of those affected by cancer themselves rated their care situation as good, very good or excellent – and thus even better than the other respondents. The main reasons for this are the good healthcare system in Switzerland, the wide range of services, the good care provided by staff, the quality of facilities, access to treatment and the unproblematic exchange of information. For instance, the medical and nursing care in hospitals is rated positively among the entirety of respondents (around 80%), and a large majority is also satisfied with the drug therapy provided. Only a few respondents criticised the therapies or the quality of care.

The cancer sufferers themselves assign the greatest importance to the support of relatives and to specialists (84% each). Hospital care (78%), general practitioners (70%) and health insurance companies (66%) are also very important for patients in terms of care and information, followed by conversations with other patients (47%), the Swiss Cancer League (34%), psychologists (31%), Spitex (29%), psychiatrists (23%), self-help organisations (22%) and patient organisations (19%).

The enormous amount of effort that goes into researching tumour diseases is also appreciated by Swiss citizens. In the survey, for example, a clear majority of 57 percent believe that good progress has been made in cancer research in the last five years; only a quarter of all participants believe that there have been no or hardly any new scientific findings in the recent past. More than half of the respondents are also optimistic that tumour diseases will be completely curable in the future.

Room for improvement in cancer prevention, early diagnosis, and aftercare


Nevertheless, the survey also reveals clearly that on closer inspection there is still a definite need for action. Among all respondents, about 15 percent each were dissatisfied with early cancer detection and cancer prevention. Almost a quarter would also welcome better psychological support. Among those actually suffering from cancer, 47 percent would have been glad if their tumour had been discovered earlier. In addition, 36 percent would have liked to be given prevention information earlier. Many have to deal with physical, psychological and economic consequences for years to come. Thus 46 percent of those currently ill are suffering from the physical consequences and about one-third from a reduced quality of life. Even among former sufferers, the loss of quality of life and the psychological consequences are still felt by 25 to 30 percent. And yet the next of kin struggle with such repercussions even more than the patients themselves: 10 percent have the dramatic feeling that the cancer has destroyed their lives. Of those currently dealing with cancer or who have previously had it, more than half consider it the most defining event in their lives, but 24 percent believe that the disease has given them a “second chance at life”.

Through this extensive survey of the population, a representative picture of the quality of care for cancer patients in Switzerland was obtained for the first time. On the one hand, it brought out the very high acceptance of the current care provision, but on the other, it allowed weaknesses to be identified in areas such as prevention, early detection and psychological care.

Reference

  1. Swiss Cancer Report 2021 https://dam-api.bfs.admin.ch/hub/api/dam/assets/19305696/master

The survey


For the representative survey on cancer patient care commissioned by MSD and conducted by gfs.bern, 1,510 randomly selected people throughout Switzerland were surveyed in detail by online questionnaire or telephone interview at the end of last year (November/December 2021). Three-quarters of the respondents stated that a person close to them or at least someone they know had been or was currently affected by cancer. A total of eleven percent (136 people) had personal experience with cancer themselves, and three percent were suffering from cancer at the time of the survey. The patients had undergone surgery (76%), chemotherapy (32%), radiotherapy (29%), targeted therapy (18%), hormone therapy (15%), alternative therapy (14%) or immunotherapy (11%).

Research institute gfs.bern


The research institute gfs.bern ag, which has overall responsibility for the survey, has an extremely long track record in empirical social research. Founded in 1959 as the Society for the Promotion of Empirical Social Research in Switzerland (GfS), it has been conducting socio-empirical research with a focus on political and communication research since 1986 as a separate division of GfS-Forschungsinstitut AG and since 2004 under its own name gfs.bern ag.

gfs.bern sees itself as a methodological full-service provider with proven specialities in relation to content. With respect to its market presence, the company aspires to quality leadership in the field of applied social research (specifically survey research with face-to-face, telephone, online and written interviews), and has successfully maintained this lead in the analysis of political opinion-forming processes for some 20 years. gfs.bern has played a key role in shaping empirical social research on socio-political and direct-democratic decision-making processes in Switzerland. gfs.bern also has many years’ experience in monitoring political and policy processes. Current teaching assignments at the Universities of Zurich, Berne, and Fribourg as well as at various universities of applied sciences help the company to make the knowledge thus gained available in education and to regularly engage in scientific reflection on their own work. For further information, see www.gfsbern.ch.

Media contact gfs.bern


Lukas Golder

Co-Director gfs.bern



lukas.golder@gfs.bern

MSD Merck Sharp & Dohme in Switzerland


In Switzerland, MSD employs around 1,000 people at five locations in the cantons of Lucerne and Zurich. At our premises in Zurich, in “The Circle”, we operate the newly opened global innovation and development hub. Our main therapeutic areas are oncology, infectious diseases, immunology and diabetes. We also have a broad portfolio of vaccines for the prevention of diseases in children, adolescents and adults. MSD has one of the largest clinical research programmes, and Switzerland participates with more than 30 clinical trials annually. At our site in Schachen, we manufacture medicines for global clinical trials and operate a forensic laboratory. MSD also assumes local responsibility for the community and has been involved for years in the “Trend Days Health Lucerne” and in the Alliance for Health Literacy, among other things. In 2022, MSD received the “Top Employer Switzerland” award for the tenth time in a row. For more information, please visit us at msd.ch, en.msd-animal-health.ch and follow us on Twitter, LinkedIn, Facebook and YouTube.

Media contact MSD Switzerland                                                     

Dr. phil. Caroline Hobi

Associate Director – Policy & Communications

caroline.hobi@msd.com 

Go to all press releases

                                                                                            

Go to all press releases

MSD Merck Sharp & Dohme AG, a leading global biopharmaceutical company based in Lucerne and Zurich has been officially certified as a Top Employer 2022 in Switzerland for the 10th consecutive time in a row. This recognition reflects a variety of benefits that MSD offers to its employees such as a newly launched Working-from-Home policy as well as a generous 16-week gender-neutral parental leave.

From among various companies evaluated in Switzerland, MSD has been certified as ‘Top Employer Switzerland’ by the independent Top Employers Institute for the tenth time in a row. Each year, the Top Employers Institute certifies organizations that are focused on putting their employees first and provide an attractive workplace environment that encourages professional and personal development.

Crucial factors for gaining the Top Employer Certification

Important factors for winning the Award include above-average ratings under the headings Human Resource Management, Remuneration and Social Security, Career Opportunities, Working Conditions, Education & Training, as well as Corporate Culture. The certification is based on the participation and results of the HR Best Practices Survey. MSD scored highly in all survey categories, particularly in the topics of Employee Engagement, which takes into consideration Well-being, as well as Rewards & Recognition. One more top scorer is the area of Unity, which is comprised of Ethical Integrity, Values, Diversity & Inclusion and Work environment. Judeke Frederiks, HR Director Switzerland comments, “We are honored to be recognized as a Top Employer in Switzerland once again. The 10th award we received underlines our ongoing commitment to creating flexible working conditions and an attractive workplace. We are proud to be above benchmark in many areas, especially in employee well-being – evaluations that are crucial in the best of times and even more important during the actual unprecedented times of the ongoing pandemic.”

Employee benefits

Since 2020, all new parents, regardless of gender, are offered 16 weeks with 100% pay within the first 12 months following the birth or adoption of a child. This policy is one of the most generous and inclusive in Switzerland, compared to the two weeks that have been legally required in Switzerland. In the same year, MSD instituted a new policy giving full flexibility to employees and their managers to determine how much they work remotely. In addition, MSD has put increased emphasis on working in digital ways becoming a more agile organization and more focused on growth and learning.

Diversity & Inclusion

MSD is demonstrating a strong focus on Diversity and Inclusion, for example through the many internal networks like the Women’s network, Next Generation network, LGBTQI network and our network for employees from African descent. MSD will continue to expand these networks.

The mentioned initiatives are big milestones in terms of benefits for all MSD employees in Switzerland, in line with its commitment to diversity, inclusion and wellbeing. More importantly, it reflects the company values and understanding on how to achieve the best possible balance between private life, family, and career.

About Top Employer

Top Employers Institute is the global authority on recognizing excellence in people practices. The Institute helps accelerate these practices to enrich the world of work. Through the Certification Program, participants can be certified and recognized as an employer of choice. Established more than 25 years ago, Top Employers Institute has certified over 1 600 organizations in 119 countries and regions. These certified companies positively impact the lives of over 6 900 000 employees globally. Crucial factors for gaining the Top Employer Award include above-average ratings under the headings Human Resource Management, Remuneration and Social Security, Career Opportunities, Working Conditions, Education and Training, and Corporate Culture. Only those companies with above-average performance in all these areas are awarded the Top Employer quality label. Further information can be accessed under the following webpage: www.top-employers.com.

About MSD in Switzerland

MSD Switzerland employs over 1’000 people working in local, regional and global functions across four sites in the canton of Lucerne and one site in the canton of Zurich. Our business activities are subdivided in the two divisions, Human Health and Animal Health. MSD Human Health covers a broad range of biopharmaceuticals. Our areas of research and development are focusing on Oncology and Immuno-Oncology as well as Vaccines to prevent diseases for children, young people, and adults against Human Papilloma Virus (HPV), Ebola, Hepatitis, Pneumococcus, Meningococcus, Measles, Rubella, Chickenpox and Herpes Zoster. In addition, MSD is conducting research in the area of infectious diseases to find new therapeutic approaches for antibiotic resistance, HIV/Aids and Hepatitis C. Further research focuses include Immunology (auto-immune diseases) as well as Diabetes. MSD has a long-lasting legacy in contributing to major public health challenges, such as River Blindness, Ebola and SARS-CoV-2.
MSD Animal Health develops and markets products for the prevention, treatment and control of disease in farm animals and pets. With the most innovative and largest product portfolio for animal health in Switzerland, MSD contributes substantially to animals’ well-being.
Our company has one of the largest clinical research programs worldwide. MSD Switzerland conducts 35 clinical trials per year for which the required medicines are manufactured at our research & development site in Schachen. The Schachen site operates since 2018 one of the three MSD forensic laboratories worldwide, investigating in manipulations and counterfeiting of MSD products – an important contribution to patient safety.
At the newly opened Zurich site “The Circle”, our company sets the focus on research & development, data management and the commercialization of our medicines and vaccines. The Zurich hub offers a state-of-the-art work environment where our empowered, culturally diverse and inclusive workforce focuses on scientific excellence to improve people’s health.
MSD Switzerland plays an active role in its community and supports a range of local and regional initiatives as for example MSD for mothers, the health congress “Trendtage Gesundheit Luzern”, and the Swiss City Marathon Lucerne. Since 2013, MSD Switzerland has been continuously certified as a Top Employer and is pioneering a gender-neutral parental leave program for employees.

For more information www.msd.chwww.de.msd-animal-health.chFollow-us on TwitterLinkedIn, Facebook and YouTube.

About MSD

For more than 130 years, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. We demonstrate our commitment to patients and population health by increasing access to healthcare through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to prevent and treat diseases that threaten people and animals — including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases — as we aspire to be the premier research-intensive biopharmaceutical company in the world.

For more information, visit http://www.msd.com and connect with us on TwitterLinkedIn and YouTube.

Media department

MSD Switzerland

media.switzerland@merck.com | Tel. 058 618 30 30
Jean-Blaise Defago (Policy & Communications Director)

Copyright © 2022 Merck & Co., Inc., Kenilworth, NJ, USA and its affiliates. All rights reserved.

CH-NON-01518, 01/2022

>> Go to all press releases

Go to all press releases

Zurich, December 9, 2021 – MSD Merck Sharp & Dohme AG known as Merck & Co, Inc, Kenilworth, N.J., USA in the United States and Canada (NYSE: MRK) – has opened the doors to its new Innovation and Development Hub in Zurich. The new MSD Zurich Hub at “The Circle” at Zurich Airport brings together more than 250 of MSD’s top R&D and marketing specialists from around the world.

MSD established a new globally-focused Innovation and Development Hub in Zurich, Switzerland, in line with its commitment to scientific excellence. The MSD Zurich Hub will further strengthen the company’s focus on innovative solutions for healthcare challenges using data processing, artificial intelligence and machine learning.

Dr Dean Li, president of MSD Research Laboratories, says: “Zurich provides an exceptional academic and life sciences ecosystem. The new MSD Hub will be a unique place where teams from all over the world collaborate and innovate in pursuit of MSD’s mission to save and improve lives.”

The global innovation hub at “The Circle” is a state-of-the-art activity-based working environment that fosters cross-functional collaboration. It co-locates some of MSD’s global and regional functions including Analytics, Biostatistics, Clinical Data Management, Data Science, Health Care Technology Assessment, Market Access, Marketing, Medical and Scientific Affairs, Real-World Evidence.

MSD has been operating in Switzerland for close to 60 years with four locations based in the Canton of Luzern. MSD has contributed to the development of the Swiss bio-pharmaceutical industry since 1963, when MSD first established its presence in Lucerne.

Today, MSD Switzerland employs around 1’000 people working in local, regional, and global functions in Human Health, Research and Development, Animal Health and Manufacturing.

“The Hub will be home to more than 250 people from a wide range of geographic backgrounds and functions, giving us the diversity of thought and experience required to continue to advance lifesaving solutions for patients,” said Frank Clyburn, executive vice president and president of Human Health for MSD.

The MSD Zurich Hub offices at The Circle have opened to employees at beginning of October 2021 in compliance with the applicable protective measures.

About MSD in Switzerland
MSD Switzerland employs over 1’000 people working in local, regional and global functions across four sites in the canton of Lucerne and one site in the canton of Zurich. Our business activities are subdivided in the two divisions, Human Health and Animal Health. MSD Human Health covers a broad range of biopharmaceuticals. Our areas of research and development are focusing on Oncology and Immuno-Oncology as well as Vaccines to prevent diseases for children, young people, and adults against Human Papilloma Virus (HPV), Ebola, Hepatitis, Pneumococcus, Meningococcus, Measles, Rubella, Chickenpox and Herpes Zoster. In addition, MSD is conducting research in the area of infectious diseases to find new therapeutic approaches for antibiotic resistance, HIV/Aids and Hepatitis C. Further research focuses include Immunology (auto-immune diseases) as well as Diabetes. MSD has a long-lasting legacy in contributing to major public health challenges, such as River Blindness, Ebola and SARS-CoV-2.

MSD Animal Health develops and markets products for the prevention, treatment and control of disease in farm animals and pets. With the most innovative and largest product portfolio for animal health in Switzerland, MSD contributes substantially to animals’ well-being.

Our company has one of the largest clinical research programs worldwide. MSD Switzerland conducts 35 clinical trials per year for which the required medicines are manufactured at our research & development site in Schachen. The Schachen site operates since 2018 one of the three MSD forensic laboratories worldwide, investigating in manipulations and counterfeiting of MSD products – an important contribution to patient safety.

At the newly opened Zurich site “The Circle”, our company sets the focus on research & development, data management and the commercialization of our medicines and vaccines. The Zurich hub offers a state-of-the-art work environment where our empowered, culturally diverse and inclusive workforce focuses on scientific excellence to improve people’s health.

MSD Switzerland plays an active role in its community and supports a range of local and regional initiatives as for example MSD for mothers, the health congress “Trendtage Gesundheit Luzern”, and the Swiss City Marathon Lucerne. Since 2013, MSD Switzerland has been continuously certified as a Top Employer and is pioneering a gender-neutral parental leave program for employees.

For more information www.msd.chwww.de.msd-animal-health.chFollow-us on TwitterLinkedIn, Facebook and YouTube.

About MSD
For more than 130 years, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. We demonstrate our commitment to patients and population health by increasing access to healthcare through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to prevent and treat diseases that threaten people and animals — including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases — as we aspire to be the premier research-intensive biopharmaceutical company in the world.

For more information, visit http://www.msd.com and connect with us on TwitterLinkedIn and YouTube.

MSD Switzerland
media.switzerland@merck.com | Tel. 058 618 30 30
Jean-Blaise Defago (Policy & Communications Director)

© 2021 MSD Merck Sharp & Dohme AG, Werftestrasse 4, 6005 Luzern. Alle Rechte vorbehalten.

CH-NON-01456, 12/21

Go to all press releases